Topical interleukin 1 receptor antagonist for treatment of dry eye disease: A randomized clinical trial

JAMA Ophthalmology

Volumn 131, Issue 6, 2013, Pages 715-723

  Amparo, Francisco ^a   Dastjerdi, Mohammad H ^a   Okanobo, Andre ^a   Ferrari, Giulio ^a   Smaga, Leila ^a   Hamrah, Pedram ^a   Jurkunas, Ula ^a   Schaumberg, Debra A ^b   Dana, Reza ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONJUNCTIVITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEIBOMIAN GLAND; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TEAR FILM;

ADMINISTRATION, OPHTHALMIC; ADULT; AGED; BOSTON; CHI-SQUARE DISTRIBUTION; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; FEMALE; FLUORESCEIN; FLUORESCENT DYES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MEIBOMIAN GLANDS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879058696     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.195     Document Type: Article

References (43)

1. International Dry Eye WorkShop Study Group. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92.
2. Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922-1929.
3. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318-326. (Pubitemid 36904081)
4. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol. 2009;127(6):763-768.
5. Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol . 2007;143(3):409-415.
6. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412-1419. (Pubitemid 36842481)
7. Gupta N, Prasad I, Jain R, D'Souza P. Estimating the prevalence of dry eye among Indian patients attending a tertiary ophthalmology clinic. Ann Trop Med Parasitol. 2010;104(3):247-255.
8. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379-387.
9. Fabre EJ, Bureau J, Pouliquen Y, Lorans G. Binding sites for human interleukin 1α, γ-interferon and tumor necrosis factor on cultured fibroblasts of normal cornea and keratoconus. Curr Eye Res. 1991;10(7):585-592.
10. Rosenbaum JT, Planck ST, Huang XN, Rich L, Ansel JC. Detection of mRNA for the cytokines, interleukin-1α and interleukin-8, in corneas from patients with pseudophakic bullous keratopathy. Invest Ophthalmol Vis Sci. 1995;36(10):2151-2155.
11. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19(3):201-211. (Pubitemid 29500267)
12. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283-2292. (Pubitemid 32848857)
13. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83(3):526-535. (Pubitemid 43902774)
14. Fini ME, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci. 1990;31(9):1779-1788. (Pubitemid 20350902)
15. Sha Y, Markovic-Plese S. A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases. Self Nonself. 2011;2(1):35-42.
16. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci. 2000;41(9):2544-2557. (Pubitemid 30624381)
17. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720-3732.
18. Yamada J, Zhu SN, Streilein JW, Dana MR. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci. 2000;41(13):4203-4208.
19. Keane-Myers AM, Miyazaki D, Liu G, Dekaris I, Ono S, Dana MR. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci. 1999;40(12):3041-3046. (Pubitemid 29521624)
20. Yamada J, Dana MR, Sotozono C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res. 2003;76(2):161-167. (Pubitemid 36263341)
21. Le Loët X, Nordström D, Rodriguez M, et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol. 2008;35(8):1538-1544.
22. Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 2012;154(1):63-71.
23. Sall K, Stevenson OD, Mundorf TK, Reis BL; CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease [published correction appears in Ophthalmology . 2000;107(7):1220]. Ophthalmology . 2000;107(4):631-639. (Pubitemid 30191329)
24. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf . 2003;1(3):107-126. (Pubitemid 41263900)
25. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615-621. (Pubitemid 30327337)
26. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90-100.
27. Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol . 2008;126(8):1046-1050.
28. Chotikavanich S, de Paiva CS, Li DQ, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203-3209.
29. Goyal S, Chauhan SK, Zhang Q, Dana R. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch Ophthalmol. 2009;127(7):882-887.
30. Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1β, TNF-α and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82(4):588-596. (Pubitemid 43122089)
31. El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, Dana R. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci. 2009;50(8):3802-3807.
32. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2(3):243-253.
33. Zheng X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest Ophthalmol Vis Sci. 2010;51(6):3083- 3091.
34. Wilson SE, Esposito A. Focus on molecules: interleukin-1: a master regulator of the corneal response to injury. Exp Eye Res. 2009;89(2):124-125.
35. Kimura K, Teranishi S, Nishida T. Interleukin-1β-induced disruption of barrier function in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2009;50(2):597-603.
36. Gabay E, Wolf G, Shavit Y, Yirmiya R, Tal M. Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain. 2011;15(3):242-248.
37. Grene RB, Lankston P, Mordaunt J, Harrold M, Gwon A, Jones R. Unpreserved carboxymethylcellulose artificial tears evaluated in patients with keratoconjunctivitis sicca. Cornea. 1992;11(4):294-301.
38. Raibekas AA, Bures EJ, Siska CC, Kohno T, Latypov RF, Kerwin BA. Anion binding and controlled aggregation of human interleukin-1 receptor antagonist. Biochemistry. 2005;44(29):9871-9879. (Pubitemid 41033453)
39. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790- 1794. (Pubitemid 41400017)
40. Goto E, Yagi Y, Matsumoto Y, Tsubota K. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol. 2002;133(2):181-186. (Pubitemid 34072045)
41. Montés-Micó R, Cáliz A, Alió JL. Wavefront analysis of higher order aberrations in dry eye patients. J Refract Surg. 2004;20(3):243-247. (Pubitemid 38657014)
42. Lu L, Reinach PS, Kao WW. Corneal epithelial wound healing. Exp Biol Med (Maywood). 2001;226(7):653-664. (Pubitemid 32619604)
43. Belmonte C, Acosta MC, Gallar J. Neural basis of sensation in intact and injured corneas. Exp Eye Res. 2004;78(3):513-525. (Pubitemid 38183329)